PL2207775T3 - Pochodne 4-benzyloamino-1-karboksyacylo-piperydyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic - Google Patents
Pochodne 4-benzyloamino-1-karboksyacylo-piperydyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnicInfo
- Publication number
- PL2207775T3 PL2207775T3 PL08848438T PL08848438T PL2207775T3 PL 2207775 T3 PL2207775 T3 PL 2207775T3 PL 08848438 T PL08848438 T PL 08848438T PL 08848438 T PL08848438 T PL 08848438T PL 2207775 T3 PL2207775 T3 PL 2207775T3
- Authority
- PL
- Poland
- Prior art keywords
- carboxyacyl
- benzylamino
- hyperlipidemia
- arteriosclerosis
- diseases
- Prior art date
Links
- 206010003210 Arteriosclerosis Diseases 0.000 title 1
- 208000031226 Hyperlipidaemia Diseases 0.000 title 1
- 208000011775 arteriosclerosis disease Diseases 0.000 title 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98545607P | 2007-11-05 | 2007-11-05 | |
| EP08848438A EP2207775B1 (en) | 2007-11-05 | 2008-11-03 | 4-benzylamino-1-carboxyacyl-piperidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis |
| PCT/EP2008/064859 WO2009059943A1 (en) | 2007-11-05 | 2008-11-03 | 4-benzylamino-1-carboxyacyl-piperidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2207775T3 true PL2207775T3 (pl) | 2012-08-31 |
Family
ID=40343337
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11188373T PL2463282T3 (pl) | 2007-11-05 | 2008-11-03 | Pochodne 4-benzyloamino-1-karboksyacylopiperydyny jako inhibitory CETP do leczenia chorób takich jak hiperlipidemia lub miażdżyca tętnic |
| PL08848438T PL2207775T3 (pl) | 2007-11-05 | 2008-11-03 | Pochodne 4-benzyloamino-1-karboksyacylo-piperydyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11188373T PL2463282T3 (pl) | 2007-11-05 | 2008-11-03 | Pochodne 4-benzyloamino-1-karboksyacylopiperydyny jako inhibitory CETP do leczenia chorób takich jak hiperlipidemia lub miażdżyca tętnic |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US8193349B2 (pl) |
| EP (2) | EP2207775B1 (pl) |
| JP (1) | JP5555635B2 (pl) |
| KR (1) | KR101564793B1 (pl) |
| CN (1) | CN101910150B (pl) |
| AR (1) | AR069165A1 (pl) |
| AT (1) | ATE550333T1 (pl) |
| AU (1) | AU2008324243B2 (pl) |
| BR (1) | BRPI0819223A2 (pl) |
| CA (1) | CA2704633C (pl) |
| CL (1) | CL2008003284A1 (pl) |
| CY (1) | CY1112706T1 (pl) |
| DK (1) | DK2207775T3 (pl) |
| EA (1) | EA022912B1 (pl) |
| ES (2) | ES2381518T3 (pl) |
| HR (1) | HRP20120476T1 (pl) |
| JO (1) | JO2732B1 (pl) |
| MX (1) | MX2010004929A (pl) |
| PE (1) | PE20090982A1 (pl) |
| PL (2) | PL2463282T3 (pl) |
| PT (2) | PT2207775E (pl) |
| SI (1) | SI2207775T1 (pl) |
| TW (1) | TWI426910B (pl) |
| WO (1) | WO2009059943A1 (pl) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101878199B (zh) | 2007-12-03 | 2013-09-18 | 诺瓦提斯公司 | 用于治疗例如高血脂或动脉硬化疾病的作为cetp抑制剂的1，2-二取代的-4-苄基氨基-吡咯烷衍生物 |
| GEAP202213376A (en) | 2009-06-17 | 2022-02-25 | Vertex Pharmaceuticals Incorporated Us | Inhibitors of influenza viruses replication |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| CA2819648C (en) | 2010-12-03 | 2018-05-01 | Epizyme, Inc. | Substituted purine and 7-deazapurine compounds |
| EP2668507B1 (en) | 2011-01-26 | 2017-08-23 | INSERM - Institut National de la Santé et de la Recherche Médicale | Method for assessing a subject's risk of having a cardiovascular disease. |
| NZ619699A (en) * | 2011-07-05 | 2016-03-31 | Vertex Pharma | Processes and intermediates for producing azaindoles |
| PL2729142T3 (pl) * | 2011-07-08 | 2018-10-31 | Novartis Ag | Sposób leczenia miażdżycy tętnic u osobników z wysokim poziomem triglicerydów |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| RS56796B1 (sr) | 2011-11-14 | 2018-04-30 | Regeneron Pharma | Kompozicije i postupci za uvećanje mišićne mase i jačine mišića specifičnim antagonizovanjem gdf8 i/ili aktivina a |
| BR112014029295B1 (pt) * | 2012-05-25 | 2021-04-27 | Nutech Ventures | Ciclobutenos e ciclobutanos anfifílicos e composição farmacêutica que os compreende |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| TW201536814A (zh) | 2013-07-25 | 2015-10-01 | Novartis Ag | 用於治療心臟衰竭之合成環狀多肽 |
| PE20160991A1 (es) | 2013-07-25 | 2016-10-15 | Novartis Ag | Bioconjugados de polipeptidos de apelina sintetica |
| TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| US9296727B2 (en) | 2013-10-07 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines |
| HUE052178T2 (hu) | 2013-11-13 | 2021-04-28 | Vertex Pharma | Eljárások influenzavírus-replikáció inhibitorainak elõállítására |
| WO2016116842A1 (en) | 2015-01-23 | 2016-07-28 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
| CN104788482B (zh) * | 2015-01-23 | 2016-09-14 | 沧州普瑞东方科技有限公司 | 一种制备2-氨基嘧啶-5-硼酸频那醇酯的方法 |
| JP6877357B2 (ja) | 2015-04-15 | 2021-05-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法 |
| JP6857617B2 (ja) | 2015-05-13 | 2021-04-14 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤 |
| WO2016183116A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| US11248044B2 (en) | 2018-03-01 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US4617307A (en) | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
| US4889861A (en) | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
| RU2086544C1 (ru) | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
| US5508272A (en) | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
| MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
| TW313568B (pl) | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
| US6140342A (en) | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
| GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| CA2345103C (en) | 1998-09-25 | 2011-04-26 | Monsanto Company | (r)-chiral halogenated 1-substitutedamino-(n+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity |
| AUPP818099A0 (en) | 1999-01-14 | 1999-02-11 | Fujisawa Pharmaceutical Co., Ltd. | New n-containing heterocyclic compounds |
| US6458849B1 (en) | 1999-09-23 | 2002-10-01 | G.D. Searle & Co. | use of substituted N,N-disubstituted mercapto amino compounds for inhibiting cholesteryl ester transfer protein activity |
| IL153115A0 (en) | 2000-06-16 | 2003-06-24 | Curis Inc | Angiogenesis-modulating compositions and uses |
| GB0021885D0 (en) | 2000-09-06 | 2000-10-18 | Fujisawa Pharmaceutical Co | New use |
| US7109204B2 (en) | 2001-08-01 | 2006-09-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| KR101476067B1 (ko) | 2002-09-06 | 2014-12-23 | 인설트 테라페틱스, 인코퍼레이티드 | 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체 |
| TW200408393A (en) | 2002-10-03 | 2004-06-01 | Ono Pharmaceutical Co | Antagonist of lysophosphatidine acid receptor |
| WO2004101529A1 (ja) | 2003-05-19 | 2004-11-25 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびその医薬用途 |
| WO2005033082A2 (en) | 2003-09-30 | 2005-04-14 | Pfizer Products Inc. | Cetp inhibitors and metabolites thereof |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| ATE433984T1 (de) | 2004-03-26 | 2009-07-15 | Lilly Co Eli | Verbindungen und verfahren zur behandlung von dyslipidämie |
| UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| MY139887A (en) | 2004-04-02 | 2009-11-30 | Mitsubishi Tanabe Pharma Corp | Tetrahydronaphthyridine derivatives and a process for preparing the same. |
| US20060063803A1 (en) | 2004-09-23 | 2006-03-23 | Pfizer Inc | 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds |
| US7700774B2 (en) | 2004-12-20 | 2010-04-20 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds and their pharmaceutical compositions |
| US20060270675A1 (en) | 2005-03-10 | 2006-11-30 | Groneberg Robert D | Inhibitors of cholesterol ester transfer protein |
| WO2006098394A1 (ja) | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | 脂質吸収抑制方法および脂質吸収抑制剤 |
| MY150958A (en) | 2005-06-16 | 2014-03-31 | Astrazeneca Ab | Compounds for the treatment of multi-drug resistant bacterial infections |
| JP4258499B2 (ja) * | 2005-07-25 | 2009-04-30 | ヤマハ株式会社 | 吹奏電子楽器の音源制御装置とプログラム |
| EP1987000A2 (en) | 2006-01-13 | 2008-11-05 | Schering Corporation | Diaryl piperidines as cb1 modulators |
| PE20071025A1 (es) | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
| WO2007107843A1 (en) | 2006-03-22 | 2007-09-27 | Pfizer Products Inc. | Methods of treatment with cetp inhibitors |
| TW200808731A (en) | 2006-03-30 | 2008-02-16 | Tanabe Seiyaku Co | A process for preparing tetrahydroquinoline derivatives |
| EP2049517B1 (en) * | 2006-07-20 | 2013-11-27 | Novartis AG | Amino-piperidine derivatives as cetp inhibitors |
| JP4834699B2 (ja) | 2007-07-30 | 2011-12-14 | 田辺三菱製薬株式会社 | 医薬組成物 |
| JP4846769B2 (ja) | 2007-07-30 | 2011-12-28 | 田辺三菱製薬株式会社 | 医薬組成物 |
| CN101878199B (zh) | 2007-12-03 | 2013-09-18 | 诺瓦提斯公司 | 用于治疗例如高血脂或动脉硬化疾病的作为cetp抑制剂的1，2-二取代的-4-苄基氨基-吡咯烷衍生物 |
| CA2707989A1 (en) | 2007-12-07 | 2009-06-11 | Novartis Ag | Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases |
-
2008
- 2008-11-03 SI SI200830588T patent/SI2207775T1/sl unknown
- 2008-11-03 JP JP2010532558A patent/JP5555635B2/ja not_active Expired - Fee Related
- 2008-11-03 EA EA201000750A patent/EA022912B1/ru not_active IP Right Cessation
- 2008-11-03 ES ES08848438T patent/ES2381518T3/es active Active
- 2008-11-03 AR ARP080104803A patent/AR069165A1/es active IP Right Grant
- 2008-11-03 PT PT08848438T patent/PT2207775E/pt unknown
- 2008-11-03 CN CN2008801240151A patent/CN101910150B/zh not_active Expired - Fee Related
- 2008-11-03 PL PL11188373T patent/PL2463282T3/pl unknown
- 2008-11-03 EP EP08848438A patent/EP2207775B1/en not_active Not-in-force
- 2008-11-03 HR HRP20120476AT patent/HRP20120476T1/hr unknown
- 2008-11-03 DK DK08848438.1T patent/DK2207775T3/da active
- 2008-11-03 AU AU2008324243A patent/AU2008324243B2/en not_active Ceased
- 2008-11-03 PT PT111883732T patent/PT2463282E/pt unknown
- 2008-11-03 PE PE2008001884A patent/PE20090982A1/es active IP Right Grant
- 2008-11-03 MX MX2010004929A patent/MX2010004929A/es active IP Right Grant
- 2008-11-03 BR BRPI0819223-5A patent/BRPI0819223A2/pt not_active Application Discontinuation
- 2008-11-03 WO PCT/EP2008/064859 patent/WO2009059943A1/en not_active Ceased
- 2008-11-03 ES ES11188373T patent/ES2434417T3/es active Active
- 2008-11-03 CA CA2704633A patent/CA2704633C/en not_active Expired - Fee Related
- 2008-11-03 PL PL08848438T patent/PL2207775T3/pl unknown
- 2008-11-03 AT AT08848438T patent/ATE550333T1/de active
- 2008-11-03 KR KR1020107012318A patent/KR101564793B1/ko not_active Expired - Fee Related
- 2008-11-03 EP EP11188373.2A patent/EP2463282B1/en not_active Not-in-force
- 2008-11-04 JO JO2008500A patent/JO2732B1/en active
- 2008-11-04 CL CL2008003284A patent/CL2008003284A1/es unknown
- 2008-11-04 TW TW097142524A patent/TWI426910B/zh not_active IP Right Cessation
- 2008-11-05 US US12/265,369 patent/US8193349B2/en active Active
-
2012
- 2012-04-18 US US13/449,347 patent/US8420641B2/en active Active
- 2012-04-26 CY CY20121100398T patent/CY1112706T1/el unknown
- 2012-06-07 US US13/490,579 patent/US8440682B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2207775T3 (pl) | Pochodne 4-benzyloamino-1-karboksyacylo-piperydyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic | |
| IL209730A0 (en) | Triazole derivatives useful for the treatment of diseases | |
| IL210262A0 (en) | Novel compounds useful for the treatment of degenerative and inflammatory diseases | |
| EP2063897A4 (en) | KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES | |
| EP2063896A4 (en) | KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES | |
| ZA201000085B (en) | 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as Met kinase inhibitors for the treatment of tumors | |
| PT2303021T (pt) | Compostos para tratamento do cancro | |
| SI2001892T1 (sl) | Spojine imidazolotiazol za zdravljenje proliferacijskih bolezni | |
| ZA200906210B (en) | 3-Imidazolyl-Indoles for the treatment of proliferative diseases | |
| SI2321295T1 (sl) | Derivati 4-(piridin-4-il)-1H-(1,3,5,)triazin-2-ona kot inhibitorji GSK3-beta za zdravljenje nevrodegenerativnih bolezni | |
| PL2254589T3 (pl) | Związki i sposoby zapobiegania lub leczenia restenozy | |
| ZA201003425B (en) | 5-cyano-thienopyridines for the treatment of tumors | |
| IL201449A0 (en) | Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases | |
| IL201562A0 (en) | Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases | |
| GB0715790D0 (en) | Drug combination for the treatment of sialorrhoea | |
| IL210066A0 (en) | Novel ortho-aminoanilides for the treatment of cancer | |
| IL192933A0 (en) | Benzoisoindole derivatives for the treatment of pain | |
| ZA201001546B (en) | Isoxazole compounds for the treatment of cancer | |
| HUP0500685A2 (en) | Pharmaceutical composition for the treatment of psychosis | |
| GB0715255D0 (en) | Thiadiazol-piperazinyl derivatives for the treatment of neurodegenerative diseases | |
| GB0715257D0 (en) | Phenylthiazolylpiperazine derivatives for the treatment of nuero degenerative diseases | |
| GB0817857D0 (en) | Compounds for the treatment of neoplasia | |
| GB0819536D0 (en) | Compounds for the treatment of neoplasia | |
| GB0715256D0 (en) | Benzylthiazolypiperazine derivatives for the treatment of neuro degenerative diseases | |
| ZA200806180B (en) | Benzoisoindole derivatives for the treatment of pain |